TheraRadar
Data updated: May 26, 2026

Eloctate (antihemophilic factor (recombinant), fc fusion protein)

Approved 2014-06-05
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2014-06-05
Patent Cliff
2021
Revenue
$70M (Q4-2025)

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
Intravenous
Dosage Forms
For Injection

Companies

Sanofi
Active Ingredient: Antihemophilic Factor (Recombinant), Fc Fusion protein , Antihemophilic Factor (Recombinant), Fc Fusion protein , Antihemophilic Factor (Recombinant), Fc Fusion protein , Antihemophilic Factor (Recombinant), Fc Fusion protein , Antihemophilic Factor (Recombinant), Fc Fusion protein , Antihemophilic Factor (Recombinant), Fc Fusion protein , Antihemophilic Factor (Recombinant), Fc Fusion protein , Antihemophilic Factor (Recombinant), Fc Fusion protein , Antihemophilic Factor (Recombinant), Fc Fusion protein , Antihemophilic Factor (Recombinant), Fc Fusion protein

Eloctate Approval History

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2014 to 2014
Jun 2014 ORIGINAL
Update · CBER biologic (Purple Book)

What Eloctate Treats

1 FDA approvals

Originally approved for its first indication in 2014 .

  • Other (1)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT04690322 STU-2020-1378 Ph 4 withdrawn POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

Eloctate FDA Label Details

Pro Intelligence Preview

Deep insights for Eloctate

Revenue Insights

  • • Q4-2025: $70M
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2021
  • • Generic/biosimilar risk

Trial Analysis

  • • Clinical trial tracking
  • • Development stage analysis

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: BLA125487 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.